Canada, n = 27 | Pittsburgh 20002, n = 48 | Germany 20083, n = 22 | Spain 20114, n = 69 | Brazil 20135, n = 79 | |
---|---|---|---|---|---|
Total n of cohort | 1417 | 555 | 1483 | 916 | 947 |
With ssSSc | 27 (2) | 48 (9) | 22 (1.5) | 69 (7.5) | 79 (8.3) |
Age at disease onset, mean (SD) | 44.4 (14.6) | 51 (range 17–78) | — | 44.9 (18.2) | 46.04 (13.1) |
Female | 24/27 (88.9) | 41/48 (85) | 20/22 (90.9) | 62/69 (89.8) | 76/79 (96.2) |
Digital ulcers | 5/27 (18.5) | 16/48 (33) | 7/22 (31.8) | 10/69 (14.5) | 19/79 (24.1) |
Articular disease | 3/27 (11.5) | 21/48 (44) | 7/22 (31.8) | 9/69 (13) | 35/79 (44.3) |
Muscular disease | 1/27 (3.7) | 2/48 (4) | 3/22 (13.6) | 2/69 (2.9) | 10/79 (12.7) |
Esophageal dysmotility | 14/25 (56.0) | 37/48 (77) | 16/22 (72.7) | 31/69 (44.9) | 64/77 (83.1) |
Interstitial lung disease | 7/27 (25.9) | 32/47 (68) | 16/22 (72.7) | 44/69 (63.7) | 37/65 (56.9) |
Pulmonary hypertension | 3/26 (11.5) | 11/48 (23) | 3/22 (13.6) | 17/69 (24.0) | 18/79 (22.8) |
Anticentromere antibodies | 9/18 (50.0) | 15/45 (33) | 8/22 (36.4) | 27/69 (24.6) | 33/79 (41.8) |
Mortality rate | 4/20 (20) | 19/48 (40) | — | 6/69 (8.7) | 6/79 (7.6) |
ssSSc: systemic sclerosis sine scleroderma.